Bioprosthetic valve thrombosis after transcatheter aortic valve replacement and pulmonary embolism due to heparin-induced thrombocytopenia: a case report.

Date publication

août 2023

Journal

Frontiers in cardiovascular medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr OHANA Mickaël

Tous les auteurs :
Faucher L, Marchandot B, Carmona A, Ohana M, Trimaille A, Morel O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37614940

Résumé

Bioprosthetic valve thrombosis is a complication of transcatheter aortic valve replacement (TAVR). It is believed to be platelet independent, mainly driven by contact phase activation, and more likely to be targeted by oral anticoagulant (OAC).

Mots clés

TAVR—transcatheter aortic valve replacement, argatroban, bioprosthetic valve dysfunction, heparin-induced thrombocytopenia, intensive unit care, pulmonary embolism, thrombosis—etiology

Référence

Front Cardiovasc Med. 2023 08 8;10:1164432